CORD-19:0036b28fddf7e93da0970303672934ea2f9944e7 / 26360-26639 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T179","span":{"begin":0,"end":279},"obj":"Sentence"},{"id":"T81565","span":{"begin":0,"end":279},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The mechanisms by which pimobendan reduces regurgitation fraction are thought to be associated with improved forward flow secondary to its inotropic and vasodilatory effects, in addition to reduced end-diastolic LV dimension, minimising secondary functional mitral regurgitation."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T135","span":{"begin":258,"end":278},"obj":"Disease"},{"id":"T134","span":{"begin":258,"end":278},"obj":"Disease"}],"attributes":[{"id":"A135","pred":"mondo_id","subj":"T135","obj":"http://purl.obolibrary.org/obo/MONDO_0001298"},{"id":"A48997","pred":"mondo_id","subj":"T134","obj":"http://purl.obolibrary.org/obo/MONDO_0001298"}],"text":"The mechanisms by which pimobendan reduces regurgitation fraction are thought to be associated with improved forward flow secondary to its inotropic and vasodilatory effects, in addition to reduced end-diastolic LV dimension, minimising secondary functional mitral regurgitation."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T93","span":{"begin":258,"end":278},"obj":"Phenotype"}],"attributes":[{"id":"A93","pred":"hp_id","subj":"T93","obj":"http://purl.obolibrary.org/obo/HP_0001653"}],"text":"The mechanisms by which pimobendan reduces regurgitation fraction are thought to be associated with improved forward flow secondary to its inotropic and vasodilatory effects, in addition to reduced end-diastolic LV dimension, minimising secondary functional mitral regurgitation."}